ProMIS Neurosciences secures $175M financing as Alzheimer’s trial hits full enrollment
ProMIS Neurosciences (NASDAQ:PMN) announced a transformational shift in its financial standing today, reporting that a massive private investment in public equity (PIPE) financing has secured the company’s clinical roadmap into 2027.























